A Review on the Biodistribution, Pharmacokinetics and Toxicity of Bismuth-Based Nanomaterials

Samireh Badrigilan,1,* Fatemeh Heydarpanahi,2,* Jalal Choupani,3,4 Mehdi Jaymand,5 Hadi Samadian,5 Mojtaba Hoseini-Ghahfarokhi,1,5 Thomas J Webster,6 Lobat Tayebi7 1Department of Radiology and Nuclear Medicine, School of Paramedical Sciences, Kermanshah University of Medical Sciences, Kermanshah, Ir...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Badrigilan S, Heydarpanahi F, Choupani J, Jaymand M, Samadian H, Hoseini-Ghahfarokhi M, Webster TJ, Tayebi L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	bismuth nanoparticles biocompatibility pharmacokinetic biodistribution and clearance Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/d63e592790e7433bbea9fbcc4c6de858
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d63e592790e7433bbea9fbcc4c6de858
record_format	dspace
spelling	oai:doaj.org-article:d63e592790e7433bbea9fbcc4c6de8582021-12-02T15:22:35ZA Review on the Biodistribution, Pharmacokinetics and Toxicity of Bismuth-Based Nanomaterials1178-2013https://doaj.org/article/d63e592790e7433bbea9fbcc4c6de8582020-09-01T00:00:00Zhttps://www.dovepress.com/a-review-on-the-biodistribution-pharmacokinetics-and-toxicity-of-bismu-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Samireh Badrigilan,1,* Fatemeh Heydarpanahi,2,* Jalal Choupani,3,4 Mehdi Jaymand,5 Hadi Samadian,5 Mojtaba Hoseini-Ghahfarokhi,1,5 Thomas J Webster,6 Lobat Tayebi7 1Department of Radiology and Nuclear Medicine, School of Paramedical Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran; 2Department of Toxicology and Pharmacology, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran; 3Department of Medical Genetics, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; 4Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 5Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran; 6Department of Chemical Engineering, Northeastern University, Boston, MA 02115, USA; 7Marquette University School of Dentistry, Milwaukee, WI 53233, USA*These authors contributed equally to this workCorrespondence: Mojtaba Hoseini-Ghahfarokhi; Lobat Tayebi Email m.hoseini@kums.ac.ir; lobat.tayebi@marquette.eduAbstract: Here, bismuth-based nanomaterials (Bi-based NMs) are introduced as promising theranostic agents to enhance image contrast as well as for the therapeutic gain for numerous diseases. However, understanding the interaction of such novel developed nanoparticles (NPs) within a biological environment is a requisite for the translation of any promising agent from the lab bench to the clinic. This interaction delineates the fate of NPs after circulation in the body. In an ideal setting, a nano-based therapeutic agent should be eliminated via the renal clearance pathway, meanwhile it should have specific targeting to a diseased organ to reach an effective dose and also to overcome off-targeting. Due to their clearance pathway, biodistribution patterns and pharmacokinetics (PK), Bi-based NMs have been found to play a determinative role to pass clinical approval and they have been investigated extensively in vivo to date. In this review, we expansively discuss the possible toxicity induced by Bi-based NMs on cells or organs, as well as biodistribution profiles, PK and the clearance pathways in animal models. A low cytotoxicity of Bi-based NMs has been found in vitro and in vivo, and along with their long-term biodistribution and proper renal clearance in animal models, the translation of Bi-based NMs to the clinic as a useful novel theranostic agent is promising to improve numerous medical applications.Keywords: bismuth nanoparticles, biocompatibility, pharmacokinetic, biodistribution and clearanceBadrigilan SHeydarpanahi FChoupani JJaymand MSamadian HHoseini-Ghahfarokhi MWebster TJTayebi LDove Medical Pressarticlebismuth nanoparticlesbiocompatibilitypharmacokineticbiodistribution and clearanceMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 15, Pp 7079-7096 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	bismuth nanoparticles biocompatibility pharmacokinetic biodistribution and clearance Medicine (General) R5-920
spellingShingle	bismuth nanoparticles biocompatibility pharmacokinetic biodistribution and clearance Medicine (General) R5-920 Badrigilan S Heydarpanahi F Choupani J Jaymand M Samadian H Hoseini-Ghahfarokhi M Webster TJ Tayebi L A Review on the Biodistribution, Pharmacokinetics and Toxicity of Bismuth-Based Nanomaterials
description	Samireh Badrigilan,1,* Fatemeh Heydarpanahi,2,* Jalal Choupani,3,4 Mehdi Jaymand,5 Hadi Samadian,5 Mojtaba Hoseini-Ghahfarokhi,1,5 Thomas J Webster,6 Lobat Tayebi7 1Department of Radiology and Nuclear Medicine, School of Paramedical Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran; 2Department of Toxicology and Pharmacology, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran; 3Department of Medical Genetics, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; 4Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 5Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran; 6Department of Chemical Engineering, Northeastern University, Boston, MA 02115, USA; 7Marquette University School of Dentistry, Milwaukee, WI 53233, USA*These authors contributed equally to this workCorrespondence: Mojtaba Hoseini-Ghahfarokhi; Lobat Tayebi Email m.hoseini@kums.ac.ir; lobat.tayebi@marquette.eduAbstract: Here, bismuth-based nanomaterials (Bi-based NMs) are introduced as promising theranostic agents to enhance image contrast as well as for the therapeutic gain for numerous diseases. However, understanding the interaction of such novel developed nanoparticles (NPs) within a biological environment is a requisite for the translation of any promising agent from the lab bench to the clinic. This interaction delineates the fate of NPs after circulation in the body. In an ideal setting, a nano-based therapeutic agent should be eliminated via the renal clearance pathway, meanwhile it should have specific targeting to a diseased organ to reach an effective dose and also to overcome off-targeting. Due to their clearance pathway, biodistribution patterns and pharmacokinetics (PK), Bi-based NMs have been found to play a determinative role to pass clinical approval and they have been investigated extensively in vivo to date. In this review, we expansively discuss the possible toxicity induced by Bi-based NMs on cells or organs, as well as biodistribution profiles, PK and the clearance pathways in animal models. A low cytotoxicity of Bi-based NMs has been found in vitro and in vivo, and along with their long-term biodistribution and proper renal clearance in animal models, the translation of Bi-based NMs to the clinic as a useful novel theranostic agent is promising to improve numerous medical applications.Keywords: bismuth nanoparticles, biocompatibility, pharmacokinetic, biodistribution and clearance
format	article
author	Badrigilan S Heydarpanahi F Choupani J Jaymand M Samadian H Hoseini-Ghahfarokhi M Webster TJ Tayebi L
author_facet	Badrigilan S Heydarpanahi F Choupani J Jaymand M Samadian H Hoseini-Ghahfarokhi M Webster TJ Tayebi L
author_sort	Badrigilan S
title	A Review on the Biodistribution, Pharmacokinetics and Toxicity of Bismuth-Based Nanomaterials
title_short	A Review on the Biodistribution, Pharmacokinetics and Toxicity of Bismuth-Based Nanomaterials
title_full	A Review on the Biodistribution, Pharmacokinetics and Toxicity of Bismuth-Based Nanomaterials
title_fullStr	A Review on the Biodistribution, Pharmacokinetics and Toxicity of Bismuth-Based Nanomaterials
title_full_unstemmed	A Review on the Biodistribution, Pharmacokinetics and Toxicity of Bismuth-Based Nanomaterials
title_sort	review on the biodistribution, pharmacokinetics and toxicity of bismuth-based nanomaterials
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/d63e592790e7433bbea9fbcc4c6de858
work_keys_str_mv	AT badrigilans areviewonthebiodistributionpharmacokineticsandtoxicityofbismuthbasednanomaterials AT heydarpanahif areviewonthebiodistributionpharmacokineticsandtoxicityofbismuthbasednanomaterials AT choupanij areviewonthebiodistributionpharmacokineticsandtoxicityofbismuthbasednanomaterials AT jaymandm areviewonthebiodistributionpharmacokineticsandtoxicityofbismuthbasednanomaterials AT samadianh areviewonthebiodistributionpharmacokineticsandtoxicityofbismuthbasednanomaterials AT hoseinighahfarokhim areviewonthebiodistributionpharmacokineticsandtoxicityofbismuthbasednanomaterials AT webstertj areviewonthebiodistributionpharmacokineticsandtoxicityofbismuthbasednanomaterials AT tayebil areviewonthebiodistributionpharmacokineticsandtoxicityofbismuthbasednanomaterials AT badrigilans reviewonthebiodistributionpharmacokineticsandtoxicityofbismuthbasednanomaterials AT heydarpanahif reviewonthebiodistributionpharmacokineticsandtoxicityofbismuthbasednanomaterials AT choupanij reviewonthebiodistributionpharmacokineticsandtoxicityofbismuthbasednanomaterials AT jaymandm reviewonthebiodistributionpharmacokineticsandtoxicityofbismuthbasednanomaterials AT samadianh reviewonthebiodistributionpharmacokineticsandtoxicityofbismuthbasednanomaterials AT hoseinighahfarokhim reviewonthebiodistributionpharmacokineticsandtoxicityofbismuthbasednanomaterials AT webstertj reviewonthebiodistributionpharmacokineticsandtoxicityofbismuthbasednanomaterials AT tayebil reviewonthebiodistributionpharmacokineticsandtoxicityofbismuthbasednanomaterials
_version_	1718387423289802752

A Review on the Biodistribution, Pharmacokinetics and Toxicity of Bismuth-Based Nanomaterials

Ejemplares similares